Asset Management One Co. Ltd. Has $20.20 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Asset Management One Co. Ltd. grew its position in Edwards Lifesciences Corporation (NYSE:EW) by 2.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 259,749 shares of the medical research company’s stock after buying an additional 7,324 shares during the period. Asset Management One Co. Ltd.’s holdings in Edwards Lifesciences were worth $20,201,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in EW. Norges Bank acquired a new position in Edwards Lifesciences in the second quarter valued at about $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of Edwards Lifesciences by 111.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after purchasing an additional 4,805,819 shares during the period. Marshall Wace LLP grew its position in shares of Edwards Lifesciences by 127.5% in the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after purchasing an additional 3,864,908 shares during the period. Jennison Associates LLC increased its stake in Edwards Lifesciences by 15.7% during the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after purchasing an additional 1,584,958 shares in the last quarter. Finally, Holocene Advisors LP raised its holdings in Edwards Lifesciences by 35.2% during the 2nd quarter. Holocene Advisors LP now owns 4,703,977 shares of the medical research company’s stock worth $367,898,000 after buying an additional 1,223,460 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,314,725.84. The trade was a 24.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,465 shares of company stock worth $3,804,610 in the last ninety days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $84.30 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The business has a 50-day moving average of $84.87 and a 200-day moving average of $80.10. The stock has a market capitalization of $48.92 billion, a price-to-earnings ratio of 36.34, a PEG ratio of 3.47 and a beta of 0.95. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on EW. Evercore ISI reiterated an “outperform” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a report on Monday. Wells Fargo & Company set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, December 18th. Royal Bank Of Canada increased their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. National Bankshares set a $92.00 price target on Edwards Lifesciences in a research note on Friday, October 31st. Finally, Robert W. Baird set a $87.00 price target on Edwards Lifesciences and gave the company a “neutral” rating in a report on Tuesday, December 16th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $94.05.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.